Related Experiment Video

Updated: Jun 26, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression

N Binkley1, S L Silverman, C Simonelli

  • 1Osteoporosis Clinical Center and Research Program, University of Wisconsin, 2870 University Avenue, Suite 100, Madison, WI 53705, USA. nbinkley@wisc.edu

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
|January 16, 2009
PubMed

Insights

Monthly ibandronate rapidly suppresses bone turnover marker CTX-I within 3 days in postmenopausal osteoporosis patients. Levels remained suppressed for 6 months, demonstrating ibandronate

Area of Science:

  • Endocrinology and Metabolism
  • Bone Biology and Osteoporosis
  • Pharmacology and Drug Efficacy

Background:

  • Postmenopausal osteoporosis (PMO) is a significant health concern.
  • Assessing drug efficacy in PMO requires monitoring bone turnover markers.
  • Serum C-terminal cross-linking telopeptide of type I collagen (CTX-I) is a key marker for bone resorption.

Purpose of the Study:

  • To evaluate the speed and pattern of serum CTX-I suppression with once-monthly oral ibandronate in women with PMO.
  • To assess the efficacy of ibandronate in reducing bone resorption markers.

Main Methods:

  • A randomized, double-blind, placebo-controlled study involving 67 women with PMO.
  • Participants received either once-monthly oral ibandronate (150 mg) or placebo for 6 months.
  • Serum CTX-I levels were measured at baseline and at multiple time points post-dose over 6 months.

Main Results:

  • Ibandronate demonstrated a rapid reduction in serum CTX-I, with a median decrease of 70.2% from baseline by day 3.
  • Serum CTX-I levels remained consistently suppressed below baseline throughout the 6-month study period in the ibandronate group.
  • A regular monthly fluctuation in CTX-I levels was observed, correlating with the dosing schedule.

Conclusions:

  • Once-monthly oral ibandronate effectively and rapidly suppresses the bone resorption marker CTX-I within 3 days.
  • Sustained suppression of CTX-I below baseline levels was maintained for 6 months.
  • Ibandronate was well-tolerated and showed a consistent pattern of efficacy in this patient population.
Abstract

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...